Vincent O'Neill - 14 Jun 2023 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Role: Chief Medical Officer
Signature: /s/ Richard Steinhart, as Attorney-in-Fact for Vincent O'Neill
Issuer symbol: BTAI
Transactions as of: 14 Jun 2023
Transactions value $: $0
Form type: 4
Filing time: 16 Jun 2023, 18:36:37 UTC
Previous filing: 18 Jun 2024
Next filing: 18 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTAI	Common Stock	Options Exercise		+521	+42.05%		1.76K	14 Jun 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTAI	Restricted Stock Units	Options Exercise	$0	-521	-8.33%	$0.00	5.73K	14 Jun 2023	Common Stock	521		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2	On March 14, 2022, the Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.